Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Harpaz

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Chemico-Biological Interactions|August 1, 1981
DNA modification in rat lungs following intratracheal or subcutaneous administration of 4-nitroquinoline-1-oxide, benzo[a]pyrene or 2-aminoanthraceneR Harpaz, C Mitchell
Clinical Pharmacology and Therapeutics|November 18, 2015
Big Data and Adverse Drug Reaction DetectionR Harpaz, W DuMochel, N H Shah
Soft Matter|April 11, 2015
Failing softly: a fracture theory of highly-deformable materialsT Goldman Boué, R Harpaz, J Fineberg, et al.
Vaccine|January 11, 2011
Potential coding error of herpes zoster (HZ) vaccination and HZ diagnosis in administrative dataM R Joesoef, J Leung, R Harpaz, et al.
Clinical Pharmacology and Therapeutics|April 10, 2014
Toward enhanced pharmacovigilance using patient-generated data on the internetR W White, R Harpaz, N H Shah, et al.
Clinical Pharmacology and Therapeutics|December 31, 2010
Biclustering of adverse drug events in the FDA's spontaneous reporting systemR Harpaz, H Perez, H S Chase, et al.
Clinical Pharmacology and Therapeutics|May 3, 2012
Novel data-mining methodologies for adverse drug event discovery and analysisR Harpaz, W DuMouchel, N H Shah, et al.
Clinical Pharmacology and Therapeutics|April 11, 2013
Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting systemR Harpaz, W DuMouchel, P LePendu, et al.
Clinical Pharmacology and Therapeutics|June 13, 2013
Response to "Logistic regression in signal detection: another piece added to the puzzle"R Harpaz, W DuMouchel, P LePendu, et al.
The Journal of Clinical Investigation|August 1, 1992
Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challengeR Harpaz, R Edelman, S S Wasserman, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Chemico-Biological Interactions|August 1, 1981
DNA modification in rat lungs following intratracheal or subcutaneous administration of 4-nitroquinoline-1-oxide, benzo[a]pyrene or 2-aminoanthraceneR Harpaz, C Mitchell
Clinical Pharmacology and Therapeutics|November 18, 2015
Big Data and Adverse Drug Reaction DetectionR Harpaz, W DuMochel, N H Shah
Soft Matter|April 11, 2015
Failing softly: a fracture theory of highly-deformable materialsT Goldman Boué, R Harpaz, J Fineberg, et al.
Vaccine|January 11, 2011
Potential coding error of herpes zoster (HZ) vaccination and HZ diagnosis in administrative dataM R Joesoef, J Leung, R Harpaz, et al.
Clinical Pharmacology and Therapeutics|April 10, 2014
Toward enhanced pharmacovigilance using patient-generated data on the internetR W White, R Harpaz, N H Shah, et al.
Clinical Pharmacology and Therapeutics|December 31, 2010
Biclustering of adverse drug events in the FDA's spontaneous reporting systemR Harpaz, H Perez, H S Chase, et al.
Clinical Pharmacology and Therapeutics|May 3, 2012
Novel data-mining methodologies for adverse drug event discovery and analysisR Harpaz, W DuMouchel, N H Shah, et al.
Clinical Pharmacology and Therapeutics|April 11, 2013
Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting systemR Harpaz, W DuMouchel, P LePendu, et al.
Clinical Pharmacology and Therapeutics|June 13, 2013
Response to "Logistic regression in signal detection: another piece added to the puzzle"R Harpaz, W DuMouchel, P LePendu, et al.
The Journal of Clinical Investigation|August 1, 1992
Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challengeR Harpaz, R Edelman, S S Wasserman, et al.
Pageof 2